PreView: a Randomized Trial of a Multi-site Intervention in Diverse Primary Care to Increase Rates of Age-Appropriate Cancer Screening
- 19 Downloads
Women aged 50–70 should receive breast, cervical (until age 65), and colorectal cancer (CRC) screening; men aged 50–70 should receive CRC screening and should discuss prostate cancer screening (PSA). PreView, an interactive, individually tailored Video Doctor Plus Provider Alert Intervention, adresses all cancers for which average risk 50–70-year-old individuals are due for screening or screening discussion.
We conducted a randomized controlled trial in 6 clinical sites. Participants were randomized to PreView or a video about healthy lifestyle. Intervention group participants completed PreView before their appointment and their clinicians received a “Provider Alert.” Primary outcomes were receipt of mammography, Pap tests (with or without HPV testing), CRC screening (FIT in last year or colonoscopy in last 10 years), and PSA screening discussion. Additional outcomes included breast, cervical, and CRC screening discussion.
A total of 508 individuals participated, 257 in the control group and 251 in the intervention group. Screening rates were relatively high at baseline. Compared with baseline screening rates, there was no significant increase in mammography or Pap smear screening, and a nonsignificant increase (18% vs 12%) in CRC screening. Intervention participants reported a higher rate of PSA discussion than did control participants (58% vs 36%: P < 0.01). Similar increases were seen in discussions about mammography, cervical cancer, and CRC screening.
In clinics with relatively high overall screening rates at baseline, PreView did not result in significant increases in breast, cervical, or CRC screening. PreView led to an increase in PSA screening discussion. Clinician-patient discussion of all cancer screenings significantly increased, suggesting that interventions like PreView may be most useful when discussion of the pros and cons of screening is recommended and/or with patients reluctant to undergo screening. Future research should investigate PreView’s impact on those who are hesitant or reluctant to undergo screening.
KEY WORDScancer screening primary care intervention
The authors would like to acknowledge the clinicians, staff, and patients at our six UCSF Clinical Research Network Sites (John Muir Medical Center – Concord, San Ramon Valley Primary Care (now known as John Muir Health), Family Care Associates, Lifelong Medical Care – West Berkeley, Highland Hospital Adult Medicine Clinic, and Southeast Medical Center) for their enthusiastic participation in the PreView randomized trial.
This study was funded by a grant from the National Cancer Institute (NIH-R01-CA-158027) and is registered with ClinicalTrials.gov (NCT02264782).
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they do not have a conflict of interest.
- 1.Agency for Healthcare Research and Quality. U.S. Preventive Services Task Force (USPSTF): An Introduction. [cited 2018; Available from: https://www.ahrq.gov/professionals/clinicians-providers/guidelines-recommendations/uspstf/index.html.
- 2.Wolf AM, et al. American Cancer Society guideline for the early detection of prostate cancer: update 2010. CA Cancer J Clin. 60(2): p. 70-98.Google Scholar
- 7.Kumar AT, Gadiyar A, Gaunkar R, Kamat AK. Assessment of readiness to quit tobacco among patients with oral potentially malignant disorders using transtheoretical model. J Educ Health Promot, 2018. prostate cancer: U.S. Preventive.Google Scholar
- 16.Arora M, et al. PRE-VIEW: Development and Pilot Testing of An Interactive Video Doctor Plus Provider Alert to Increase Cancer Screening. ISRN Prev Med, 2013. 2013.Google Scholar
- 17.SAS Institute. 2017. Cary, NCGoogle Scholar